BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Citi
Boehringer Ingelheim
Cerilliant
Teva
US Army
Harvard Business School
Federal Trade Commission
McKesson
Medtronic

Generated: January 17, 2018

DrugPatentWatch Database Preview

Theravance Biopharma Company Profile

« Back to Dashboard

Summary for Theravance Biopharma
International Patents:113
US Patents:11
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Theravance Biopharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Theravance Biopharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,872,804 Glycopeptide disulfide and thioester derivatives ➤ Subscribe
7,074,760 Polyacid glycopeptide derivatives ➤ Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives ➤ Subscribe
6,906,031 Polyacid glycopeptide derivatives ➤ Subscribe
8,541,375 Glycopeptide phosphonate derivatives ➤ Subscribe
7,265,086 Glycopeptide carboxy-saccharide derivatives ➤ Subscribe
7,157,554 Glycopeptide carboxy-saccharide derivatives ➤ Subscribe
8,003,755 Hydrochloride salts of a glycopeptide phosphonate derivative ➤ Subscribe
7,244,705 Polyacid glycopeptide derivatives ➤ Subscribe
8,859,506 Glycopeptide phosphonate derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Theravance Biopharma Drugs

Supplementary Protection Certificates for Theravance Biopharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00507 Netherlands ➤ Subscribe PRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
7 Finland ➤ Subscribe
2012002,C1292612 Lithuania ➤ Subscribe PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
/2011 Austria ➤ Subscribe PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
11/037 Ireland ➤ Subscribe PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
2012002 Lithuania ➤ Subscribe PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
2011 00033 Denmark ➤ Subscribe PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID
C/GB11/056 United Kingdom ➤ Subscribe PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
90036-2 Sweden ➤ Subscribe PRODUCT NAME: TELAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV INNEFATTANDE TELAVANCINHYDROKLORID; REG. NO/DATE: EU/1/11/705/001 20110902
C0051 France ➤ Subscribe PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
McKinsey
Chubb
Covington
Fish and Richardson
AstraZeneca
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot